Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1α activation

XIAOYU YANG1,2, HUBIN YIN1,2, YUNZHI ZHANG2, XINYUAN LI1,2, HANG TONG1, YIZHOU ZENG1, QUAN WANG1 and WEIYANG HE1

1Department of Urology, and 2Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China

Received November 16, 2017; Accepted April 17, 2018

DOI: 10.3892/ijo.2018.4376

Abstract. Overcoming the chemoresistance of bladder cancer is a pivotal obstacle in clinical treatments. Hypoxia widely exists in solid tumors and has been demonstrated to contribute to chemoresistance through hypoxia-inducible factor 1α (HIF-1α)-mediated autophagy in several types of cancer. However, it is unclear whether HIF-1α-mediated autophagy and chemoresistance occur in bladder cancer. The present study demonstrated that HIF-1α was overexpressed in 20 bladder cancer tissues compared with matched paracarcinoma tissues. Gemcitabine-induced apoptosis during hypoxia was significantly reduced compared with that observed under normoxic conditions. In addition, hypoxia activated autophagy and enhanced gemcitabine-induced autophagy. Combined treatment using gemcitabine and an autophagy inhibitor (3-methyladenine) under hypoxia significantly increased gemcitabine cytotoxicity. Furthermore, it was demonstrated that hypoxia-activated autophagy depended on the HIF-1α/BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)/Beclin1 signaling pathway. Suppressing HIF-1α inhibited autophagy, BNIP3 and Beclin1, as well as enhanced gemcitabine-induced apoptosis in bladder cancer cells under hypoxic conditions. Consequently, the results of the present study demonstrated that hypoxia-induced cytoprotective autophagy counteracted gemcitabine-induced apoptosis through increasing HIF-1α expression. Therefore, targeting HIF-1α-associated pathways or autophagy in bladder cancer may be a successful strategy to enhance the sensitivity of bladder cancer chemotherapy.

Introduction

Urinary bladder cancer has become one of the most common urological malignancies, and its incidence ranks eighth among all malignant types of cancer. It is estimated that 79,030 new cases of bladder cancer and 16,870 associated mortalities occurred in 2017 (1). Muscle-invasive bladder cancer patients are at a great risk of recurrence and metastasis subsequent to radical cystectomy. Furthermore, the 5-year survival of these patients is only 30-50% (2,3). Chemotherapy is a beneficial treatment for prolonging the survival time of patients at an advanced tumor stage. Gemcitabine, a cytosine analogue that inhibits DNA synthesis, has been widely used to treat bladder cancer, and gemcitabine in combination with other chemotherapeutic drugs has become the preferred standard treatment for advanced urothelial carcinoma (4-6). However, drug resistance leads to treatment failure in bladder cancer. Therefore, it is important to explore the underlying mechanism of gemcitabine resistance.

It has been reported that the tumor microenvironment is involved in the development of chemoresistance (7). Solid tumors are commonly exposed to a hypoxic environment due to their abnormal vascular system, treatment- or malignancy-associated anemia, and low levels of intra-tumor infusion. The resulting hypoxia becomes an important feature of the tumor microenvironment (8). The adaptive response of cells to hypoxia is achieved by altering the transcription of certain genes. Hypoxia-inducible factor 1 (HIF-1) is an important nuclear transcription factor that regulates hypoxia responses in cells. HIF-1 controls the expression of several downstream genes, which affect energy metabolism, glycolysis, angiogenesis, DNA repair, and the cell cycle progression. These genes not only control tumor proliferation and metastasis, but also promote chemotherapy resistance (9-11).

In hepatocellular carcinoma cells, autophagy is a protective mechanism involved in the resistance to chemotherapy under hypoxic conditions (12). Cell autophagy is a complex process involving lysosomal degradation of intracellularly damaged organelles and long-lived proteins, providing for the reuse of raw materials for cell survival under external conditions, such as hypoxia, a lack of growth factors or nutrient starvation.
conditions (13). It has been demonstrated that HIF-1 is involved in autophagy regulation (14). The downregulation of HIF-1α suppresses autophagy and promotes anticancer agent-induced apoptosis (15).

Therefore, in order to validate the hypothesis that HIF-1α mediates hypoxia-induced protective autophagy associated with gemcitabine resistance, the present study investigated the impact of hypoxia on cells treated with gemcitabine. Next, the study examined whether autophagy inhibition reversed the cytotoxicity of bladder cancer cells under hypoxia, and investigated the underlying mechanism of hypoxia-induced autophagy leading to gemcitabine resistance.

Materials and methods

Reagents and antibodies. The anti-light chain 3B (LC3B) antibody (1:1,000; Cat. no. L7543) was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany), the anti-p62 antibody (1:2,000; Cat. no. 610497) was obtained from BD Biosciences (New York, NY, USA), and the anti-HIF-1α antibody (1:1,000; Cat. no. 113642) was purchased from Abcam (Cambridge, MA, USA). Anti-poly(ADP-ribose) polymerase (PARP; 1:1,000; Cat. no. 95325), anti-cleaved caspase-3 (1:1,000; Cat. no. 9664S) and anti-Beclin1 antibodies (1:1,000; Cat. no. 3495S) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). An antibody against BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3; 1:500; Cat. no. sc-56167) was obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-β-actin antibody (1:1,000; Cat. no. Abm-0001) was from Zoonbio Biotechnology Co., Ltd. (Nanjing, China), while anti-rabbit (1:5,000; Cat. no. ASS1006)/mouse (1:5,000; Cat. no. ASS1021) secondary antibodies were purchased from Abgent (San Diego, CA, USA). 3-Methyladenine (3MA; 5 mM), chloroquine (CQ; 10 µM), gemcitabine and cell counting kit-8 (CCK-8) reagents were obtained from Selleck Chemicals (Houston, TX, USA). 3MA and CQ were both formulated in triple-distilled water. The bladder cancer cells were treated with 3MA or CQ for 1 h at room temperature prior to stimulation with hypoxia and GEM. RPMI-1640 medium was obtained from HyClone (GE Healthcare Life Sciences, Logan, UT, USA). Fetal bovine serum (FBS) and trypsin were purchased from Thermo Fisher Scientific, Inc. (Gibco, Waltham, MA, USA). The green fluorescent protein (GFP)-LC3 adenoviral vectors were acquired from Hanbio Biotechnology Co., Ltd. (Shanghai, China).

Tissue sample collection. A total of 20 paired specimens of bladder cancer and matched adjacent tissues were collected from the Department of Pathology, The First Affiliated Hospital of Chongqing Medical University. All specimens were histopathologically diagnosed. Among the patients, there were 16 males and 4 females, aged 50-80 years with a mean age of 66.5 years. They were admitted from January, 2013 to October, 2017. No patient received chemotherapy or radiotherapy prior to surgery. In total, 6 patients underwent transurethral resection of the bladder tumor (TURBT) and 14 patients underwent radical curative resection the bladder tumor (RC). Pathological grading and staging were determined according to the WHO 1973 criteria for grade and the 2002 TNM classification system (16,17). The study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University, and written informed consent was obtained from the patients or the patients’ families.

Cell lines and culture conditions. The human bladder cancer T24 cells were provided by the Chongqing Key Laboratory of Molecular Oncology and Epigenetics at the First Affiliated Hospital of Chongqing Medical University [Chongqing, China]; the cells were originally obtained from the American Type Culture Collection (ATCC), Manassas, VA, USA. The cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 0.1 mg/ml penicillin and 0.1 mg/ml streptomycin at 37°C. In order to simulate the hypoxic environment, a hypoxia incubator (Sanyo Electric Co., Ltd., Osaka, Japan) with 1% O2 at 37°C was used for cell cultures under hypoxic conditions, as previously described (18).

Cell viability assay. Cells were seeded in 96-well plates at 5x103 cells/well with 200 µl medium for 24 h and then treated with gemcitabine at the indicated concentrations (0, 5, 10, 20, 30, 40, 50 and 60 µM) under hypoxic or normoxic conditions for a further 24 h. In order to simulate a hypoxic environment, a hypoxia incubator (Sanyo Electric Co., Ltd.) with 1% O2 at 37°C was used to expose the cells to hypoxia. Following incubation, 10 µl CCK-8 and 100 µl medium were added into each well, and incubated for 1 h. The absorbance (450 nm) was measured by the Tecan Infinite F200/M200 type multi-function microplate reader (Tecan Group, Ltd., Männedorf, Switzerland). The viability percentage of the cells based on the optical density (OD) was calculated as follows: Cell viability (%) = (Average OD value of the experimental group - average OD value of blank group) / (average OD value of control group - average OD value of blank group) x 100%. All experiments were conducted in triplicate. The half maximal inhibitory concentration (IC50) was calculated using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA).

Annexin V/propidium iodide (PI) assay. The cells were treated as follows: i) When the cell density reached 70-80%, the cells were pre-treated with 3MA (5 mM) for 1 h, and then cells were incubated under hypoxic or normoxic conditions for 24 h with or without gemcitabine (5 µM) treatment, respectively. The specific groups were as follows: The normoxic control group, hypoxic group, hypoxia plus 3MA group, GEM group, GEM group under hypoxic conditions and gemcitabine combined with the 3MA group under hypoxic conditions. ii) When the cell density reached 40-50%, HIF-1α siRNA and NC siRNA were transfected into T24 cells for 48 h, and the cells were then incubated under hypoxic or normoxic conditions for 24 h with or without gemcitabine (5 µM) treatment, respectively. The specific groups were as follows: The normoxic control group, hypoxia group, hypoxia plus 3MA group, GEM group, GEM group under hypoxic conditions and gemcitabine combined with the 3MA group under hypoxic conditions. The cells were then trypsinized, washed with cold PBS 3 times, collected and then resuspended in 200 µl Annexin V-FITC binding buffer, which included 5 µl Annexin V-FITC and 10 µl PI for 10 min in the dark. For this, the Annexin V-FITC and PI kit (Beyotime Institute of Biotechnology, Haimen, China) was used. Subsequently, all cells were stained for 10 min in...
the dark. Apoptotic cells were measured by flow cytometry (BD Biosciences, San Jose, CA, USA).

**Electron microscopy.** Subsequent to the indicated treatments, the cells were digested by trypsin and collected by centrifugation at 1,200 x g for 10 min at room temperature. The cells were sequentially fixed with 2.5% glutaraldehyde for 2 h and 1% osmium tetroxide for 1 h, and then dehydrated with acetone and embedded in Epon resin (Sigma-Aldrich/Merck KGaA, Darmstadt, Germany) and the embedded material was then cut into 50-nm-thick sections using an ultramicrotome. Ultra-thin (50 nm) slices were double-stained with uranyl acetate and lead citrate (both from Sigma-Aldrich/Merck KGaA) for 15 min at room temperature. Subsequently, a transmission electron microscope (Hitachi-HT7700; Hitachi, Ltd., Tokyo, Japan) was used to observe the autophagosomes.

**Confocal microscopy.** Bladder cancer cells were seeded (10⁵/well) into confocal culture dishes (20 mm; NEST Biotechnology Co., Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions. Transfection reagents (siRNA-Mate; GenePharma Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions. Transfection reagents (siRNA-Mate; GenePharma Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions. Transfection reagents (siRNA-Mate; GenePharma Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions. Transfection reagents (siRNA-Mate; GenePharma Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions. Transfection reagents (siRNA-Mate; GenePharma Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions. Transfection reagents (siRNA-Mate; GenePharma Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions. Transfection reagents (siRNA-Mate; GenePharma Ltd., Wuxi, China) for 24 h, and an adenovirus vector carrying GFP-LC3 (acquired from Hanbio Biotechnology Co., Ltd., Shanghai, China) and Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) were used based according to the manufacturer's instructions.
P<0.01; Fig. 1D). These results revealed that hypoxia was a
general characteristic in bladder cancer.

**Hypoxia induces gemcitabine resistance in bladder cancer cells.** To detect the impact of hypoxia on gemcitabine resistance, the chemosensitivity of the T24 cells was examined under hypoxic or normoxic conditions. The cells were exposed to a series of concentrations of gemcitabine ranging between 0 and 60 µM for 24 h under normoxic conditions (20% O₂) or hypoxia (1% O₂). Subsequently, the CCK-8 assay was used to evaluate the cell viability (Fig. 2A). The cell viability decreased in a dose-dependent manner and was higher conditions as compared with that under normoxic conditions. The half maximal inhibitory concentration (IC₅₀) value for T24 cells under normoxic conditions was 4.104±0.6132 µM, while the IC₅₀ value of T24 cells conditions was 38.40±1.001 µM.

Therefore, the gemcitabine concentration of 5 µM was utilized for the treatment of T24 cells in subsequent experiments. Furthermore, gemcitabine caused the cleaved caspase-3 and cleavage of PARP in a dose-dependent manner (Fig. 2B). Under normoxic conditions, gemcitabine caused more significant cleaved caspase-3 and cleavage of PARP as compared with that under hypoxia (Fig. 2B). These data suggested that hypoxia reduced the chemosensitivity of bladder cancer cells to gemcitabine.
Hypoxia induces autophagy in bladder cancer cells. Previous studies (20,21) have demonstrated that hypoxia leads to resistance to gemcitabine, and it was further demonstrated that autophagy was induced during hypoxia and nutritional deficiency. Thus, the current study investigated whether hypoxia induced autophagy in bladder cancer cells. First, immunoblotting was used to confirm the occurrence of autophagy under hypoxic conditions. Hypoxia improved the expression of LC3-II, with p62 degradation occurring in a time-dependent manner (Fig. 3A). In addition, autophagy flux was examined following co-treatment with hypoxia and a lysosomal inhibitor, CQ (10 µM). Although hypoxia or CQ alone increased LC3-II levels, the combination of hypoxia with CQ resulted in a marked increase in LC3-II levels (Fig. 3B). Taken together, these data revealed that hypoxia activated autophagy in bladder cancer cells.

Hypoxia elevates gemcitabine-induced autophagy in bladder cancer cells. The current study next examined the occurrence of autophagy in bladder cancer cells treated with gemcitabine under hypoxic conditions. T24 cells were incubated in complete medium under hypoxic or normoxic conditions, with or without gemcitabine for 8 h. Exposure to hypoxia and treatment with gemcitabine increased LC3-II levels compared with the levels upon exposure to hypoxia or treatment with gemcitabine alone. In addition, the LC3-I to LC3-II conversion was almost completely abolished by the addition of 3MA (5 mM) in the gemcitabine-treated cells under hypoxic conditions or in cells exposed to hypoxia alone (Fig. 4A).

Autophagy was also observed by monitoring the formation of GFP spots using confocal microscopy. Following transfection...
using a GFP-LC3 adenovirus for 24 h, the cells were maintained in complete medium under normoxic or hypoxic conditions, with or without gemcitabine for 8 h. The number of GFP-LC3 puncta in the gemcitabine-treated cells under hypoxic conditions was significantly increased in comparison with that in the hypoxia or gemcitabine-treated cells alone. Furthermore, following pretreatment with 3MA, GFP-LC3 puncta accumulation significantly decreased in the gemcitabine-treated cells under hypoxic conditions or in cells cultured under hypoxic conditions alone (Fig. 4B and C).

Transmission electron microscopy was also used to observe autophagosomes. Autophagic vacuoles were detected following exposure to hypoxia or gemcitabine treatment alone, and the amount of autophagic vacuoles was augmented when cells were exposed to gemcitabine and hypoxia. However, following pretreatment with 3MA, the autophagic vacuoles decreased (Fig. 4D). In conclusion, these results indicated that hypoxia augmented gemcitabine-induced autophagy in bladder cancer cell lines.

Blocking autophagy enhances bladder cancer cell sensitivity to gemcitabine under hypoxic conditions. To verify that autophagy had a protective effect in bladder cancer cells obtaining resistance to gemcitabine under hypoxic conditions, 3MA, which is an inhibitor of phosphatidylinositol-3 kinase (PI3K), was utilized to inhibit autophagy. The CCK-8 assay revealed that 3MA (5 mM) strongly enhanced the inhibitory effect of gemcitabine on cell viability under hypoxic conditions (Fig. 5A).

Figure 5. Inhibition of autophagy enhanced GEM-induced apoptosis under hypoxia. T24 cells were pretreated with 3MA (5 mM) for 1 h, and then treated with or without GEM (5 µM) for 24 h under hypoxia or normoxia. (A) Cell viability was detected by the cell counting kit-8 assay. (B) Apoptotic cell percentages were detected by flow cytometry. (C) Early apoptosis (Annexin V+/PI-) and late-stage apoptosis (Annexin V+/PI+) were calculated, and are shown in the histograms. (D) Cleaved caspase-3 and PARP were measured by immunoblotting. Data represent the mean ± standard deviation from three independent experiments. **P<0.01 and *P<0.05. GEM, gemcitabine; 3MA, 3-methyladenine; PARP, poly(ADP-ribose) polymerase; PI, propidium iodide.
Annexin V-FITC/PI staining followed by flow cytometry was subsequently used to analyze apoptosis. The apoptotic percentages of T24 cells treated with gemcitabine under normoxic conditions were higher than those observed under hypoxic conditions. However, the apoptotic percentages of T24 cells treated with gemcitabine under hypoxic conditions was significantly enhanced following the suppression of autophagy with 3MA (Fig. 5B and C). A similar apoptosis enhancement was also detected using immunoblotting. Increased cleaved caspase-3 and cleavage of PARP were noted when cells were co-treated with gemcitabine and 3MA under hypoxic conditions (Fig. 5D). These results suggested that the resistance of bladder cancer cells to gemcitabine may be attributed to hypoxia-mediated protective autophagy. Decreasing autophagy may therefore enhance gemcitabine-induced apoptosis.

**HIF-1α/BNIP3/Beclin1 pathway mediates hypoxia-activated autophagy in bladder cancer cells.** To investigate the mechanism through which hypoxia induced autophagy in bladder cancer cells, the study determined whether HIF-1α was involved in the process of hypoxia-induced autophagy. To verify the hypothesis, the activation of HIF-1α and its downstream target proteins (BNIP3 and Beclin1) was first examined in bladder cancer cells under hypoxic conditions. HIF-1α, BNIP3, and Beclin1 levels were increased in a time-dependent manner under hypoxic conditions in T24 cells (Fig. 6A). A specific siRNA targeting HIF-1α was then transfected into bladder cancer cell lines to knockdown HIF-1α expression. As expected, the inhibition of HIF-1α expression decreased the levels of the HIF-1α downstream target proteins BNIP3 and Beclin1, and also reduced hypoxia-induced autophagy (Fig. 6B). The results mentioned above suggested that hypoxia promoted gemcitabine-induced autophagy. Therefore, the present study further investigated whether HIF-1α was involved in the gemcitabine-induced autophagy increase in bladder cancer cells. Following the downregulation of HIF-1α, gemcitabine failed to induce more LC3-II accumulation under hypoxic conditions (Fig. 6C). This demonstrated that HIF-1α was a main regulator of hypoxia-induced autophagy.

**HIF-1α knockdown promoted gemcitabine-induced apoptosis in bladder cancer under hypoxic conditions.** To further investigate the role of HIF-1α in gemcitabine resistance, the effects of HIF-1α knockdown on gemcitabine-induced cytotoxicity were examined. The knockdown of HIF-1α almost completely eliminated the resistance of bladder cancer cells to gemcitabine under hypoxic conditions. In addition, HIF-1α knockdown strongly inhibited cell viability compared with that in cells treated with gemcitabine under hypoxic conditions alone (Fig. 7A). Annexin V-FITC/PI staining followed by flow cytometry was used to measure apoptosis levels. The data revealed that gemcitabine-induced apoptosis increased significantly compared with that in the hypoxia group (Fig. 7B and C). However, gemcitabine-induced apoptosis of bladder cancer cells was reversed following the inhibition of HIF-1α expression. Consistently, immunoblotting demonstrated the same apoptotic changes. Knockdown of HIF-1α was observed to enhance the activation of caspase-3 and PARP cleavage (Fig. 7D). These results suggested that hypoxia-induced protective autophagy mediated by HIF-1α may lead to bladder cancer cell resistance to gemcitabine.

**Discussion**

The current study provided evidence that HIF-1α-mediated hypoxia-induced autophagy was critical to gemcitabine resistance. Autophagy was evidently induced when T24 cells were treated with hypoxia or gemcitabine alone, and it was noted that hypoxia significantly enhanced autophagy when bladder cancer cells were exposed to gemcitabine. In addition, HIF-1α expression was increased in bladder cancer tissues and bladder cancer cells treated with hypoxia. HIF-1α siRNA or treatment with the autophagy inhibitor 3MA inhibited the hypoxia-
activated autophagy and augmented the gemicitabine-induced apoptosis. Furthermore, HIF-1α strongly elevated BNIP3 and Beclin1 expression levels. Suppression of HIF-1α was observed to downregulate the expression levels of BNIP3 and Beclin1, suggesting that the HIF-1α/BNIP3/Beclin1 signaling cascade pathway was involved in hypoxia-induced autophagy. Taken together, the present study results suggested that targeting autophagy or HIF-1α increased the chemosensitivity of bladder cancer cells to gemicitabine.

Chemotherapy is an important treatment for advanced bladder cancer; however, resistance to anti-cancer drugs has been a key obstacle to further extending the survival of patients. Recent studies have suggested that the local micro-environment of the tumor (particularly hypoxia) serves a significant part in the induction of tumor resistance (21,22).

Consistent with the findings of previous studies (20,21,23), the present study found that T24 cells treated with gemicitabine under hypoxic conditions exhibited significant treatment resistance compared with that observed under normoxic conditions. The underlying mechanisms of hypoxia-induced chemoresistance are complex, and include multiple drug-resistant gene expression, reduced reactive oxygen species (ROS) levels, cell cycle arrest, gene mutations and drug concentration decreases (8,24-27). Furthermore, autophagy activation is another possible mechanism protecting cells from chemotherapeutic drug-induced apoptosis. It is generally accepted that autophagy is a mechanism of cellular defense and stress regulation. In the absence of oxygen or nutritional deficiencies, autophagy selectively removes some of the damaged organelles, including mitochondria, endoplasmic

---

Figure 7. Knockdown of HIF-1α enhanced GEM-induced apoptosis. T24 cells were transfected with HIF-1α siRNA or control siRNA for 48 h, followed by treatment with GEM (5 µM) under hypoxia for 24 h. (A) Cell viability was measured by cell counting kit-8 assay. (B) Flow cytometry was used to measure the apoptotic cell percentages. (C) Early apoptosis (Annexin V+/PI-) and late-stage apoptosis (Annexin V+/PI+) were calculated, and are shown in the histograms. (D) Cleaved caspase-3 and PARP were detected by immunoblotting. Data are shown as the mean ± standard deviation from three independent experiments. *P<0.01 and **P<0.05. HIF-1α, hypoxia-inducible factor 1α; GEM, gemicitabine; siRNA, small interfering RNA; PARP, poly(ADP-ribose) polymerase.
In recent years, it was demonstrated that autophagy was also a protective mechanism in the process of chemoresistance under hypoxic conditions in a variety of tumor cells, such as in liver, lung and colon cancer (30-32). However, whether autophagy is involved in the process of bladder cancer cell resistance to chemotherapy under a hypoxic microenvironment is not clear.

In the present study, similarly to previous studies (6,18,33), it was observed that autophagy was activated when bladder cancer cells were exposed to hypoxia, as well as to gemcitabine. Notably, autophagy was enhanced when the cells were exposed to hypoxia and gemcitabine simultaneously, including increased GFP-LC3 puncta, enhanced formation of autophagic vacuoles and upregulation of LC3-II levels. However, when autophagy was blocked by treatment with 3MA, a commonly used inhibitor of autophagy that inhibits the conversion of autophagy was blocked by treatment with 3MA, a commonly used inhibitor of autophagy that inhibits the conversion of LC3-I to LC3-II by inhibiting PI3K (34), the hypoxia-induced autophagy was significantly reduced. Furthermore, it has been demonstrated that 3MA combined with chemotherapy drugs under hypoxic conditions can effectively promote tumor cell apoptosis (14,15). As expected, 3MA reversed the chemosen-sitivity of bladder cancer cells to gemcitabine under hypoxic conditions, which was demonstrated by the enhanced cell sensitivity of bladder cancer cells to gemcitabine under hypoxic conditions, which was demonstrated by the enhanced cell proliferation inhibition, increased apoptotic cell percentage, and increased caspase-3 activation and PARP cleavage.

The adaptation of cells to hypoxia mainly depends on changes in gene transcription levels (35). HIF-1α is an oxygen-regulating subunit of HIF-1, a hypoxia-dependent protein, that serves a major hypoxic regulatory role and determines HIF-1 activity. The α subunit of HIF-1α is easily degraded at high concentrations of oxygen. After stably and rapidly accumulating in the nucleus under hypoxic conditions, HIF-1α binds with HIF-1β to activate the HIF-1 heterodi-meric complex, which promotes the expression of hypoxia target genes through combining with the hypoxia response element (33,36,37). Studies have revealed that the associations between hypoxia and autophagy are mainly through HIF-1-regulated expression of downstream target proteins BNIP3 and BNIP3L, which release Beclin1 to activate autophagy by disrupting the interaction between Beclin1 and Bcl-2/Bcl-xL complexes (33,38-40). Another study has suggested that hypoxia-induced cancer cell autophagy was an HIF-1 independent pathway. Hypoxia activated autophagy through activating AMPK-mTOR signaling (41-43). In addition, the unfolded protein region generated by the endoplasmic reticulum under hypoxic stimulation activated transcription factor 4 to induce autophagy (44-46). The present study demonstrated that the expression of HIF-1α in bladder cancer cells under hypoxic conditions was accompanied with the activation of the downstream proteins BNIP3 and Beclin1. Suppressing HIF-1α reduced the expression of BNIP3 and Beclin1, and the autophagy activation, suggesting that the HIF-1α/BNIP3/Beclin1 signaling cascade was involved in hypoxia-induced autophagy. Furthermore, when HIF-1α was upregulated under hypoxic conditions, the gemcitabine-induced apoptosis was significantly reduced. However, when HIF-1α was suppressed, gemcitabine-induced apoptosis was significantly increased. These results indicated that HIF-1α inhibited the gemcitabine apoptotic cytotoxicity in bladder cancer cells by mediating autophagy.

In conclusion, the results of the current study revealed that resistance to gemcitabine in bladder cancer cells under hypoxic conditions was due to elevated levels of autophagy, which was regulated by HIF-1α-associated signaling pathways. Therefore, the hypoxia-autophagy pathway may be a target for enhancing the effectiveness of gemcitabine chemotherapy in bladder cancer patients.

Acknowledgements

Not applicable.

Funding

This study was supported by funding from Natural Science Foundation of China (grant no. 81372758), the Natural Science Fund Project of Chongqing (grant no. cstc2013jcyjA10058), and the Innovative Project of Science Research for Postgraduate of Chongqing Municipal Education Committee (CYS15141).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

WH designed the research; XY performed the experiments; XY, HY, YZ, HT, QW, XL and YZ analyzed the data; XY wrote the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University, and written informed consent was obtained from the patients or the patients' families.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


